LeMaitre Q3 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Nasdaq lags on angst over AI spending ahead of earnings reports
Lemaitre Vascular (LMAT) Misses Q3 EPS by 3c; Offers FY22 Guidance
October 27, 2022 4:29 PM EDTLemaitre Vascular (NASDAQ: LMAT) reported Q3 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $39 million versus the consensus estimate of $40.06 million.
GUIDANCE:
Lemaitre Vascular sees FY2022 EPS of $1.02-$1.08, versus the consensus of $1.09.... More
